Medicare Enrolled

Dr. Ulka Vaishampayan, MD

Medical Oncology · Ann Arbor, MI
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Speaking/Promotional
1500 E MEDICAL CENTER DR, Ann Arbor, MI 48109
7349364000
In practice since 2006 (20 years)
NPI: 1659318640 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Vaishampayan from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vaishampayan? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Vaishampayan

Dr. Ulka Vaishampayan is a medical oncology specialist in Ann Arbor, MI, with 20 years of NPI registration. Based on federal Medicare data, Dr. Vaishampayan performed 267 Medicare services across 178 unique beneficiaries.

Between the years covered by Open Payments, Dr. Vaishampayan received a total of $1,219,156 from 36 pharmaceutical and/or device companies across 1018 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Vaishampayan is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ 267 Medicare services $1,219,156 industry payments

Medicare Practice Summary

Medicare Utilization ↗
267
Medicare services
Bottom 35% in MI for medical oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
178
Unique beneficiaries
$75
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~13 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
 84 $111 $196
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
 53 $68 $131
Telephone medical discussion, 11-20 minutes
A phone conversation with a physician lasting between 11 and 20 minutes.
 50 $49 $88
Telephone medical discussion, 21-30 minutes
A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone.
 37 $65 $131
Telephone medical discussion, 5-10 minutes
A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters.
 32 $24 $55
New patient office visit, complex (60-74 min) 11 $134 $312
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$1,219,156
Total received (2018-2024)
Avg $174,165/year across 7 years
Top 1% in MI for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
1,018
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,022,850 (83.9%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$194,666 (16.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,640 (0.1%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$103,779
2023
$153,859
2022
$145,555
2021
$88,841
2020
$129,776
2019
$302,013
2018
$295,333

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$44,596
Exelixis Inc.
$22,856
Astellas Pharma US Inc
$8,318
Gilead Sciences, Inc.
$7,325
Bayer Healthcare Pharmaceuticals Inc.
$5,652
EMD Serono Research & Development Institute, Inc.
$3,800
Merck Sharp & Dohme LLC
$3,119
Sumitomo Pharma America, Inc.
$3,100
Novartis Pharmaceuticals Corporation
$2,400
AstraZeneca Pharmaceuticals LP
$1,370
Janssen Scientific Affairs, LLC
$818
Aveo Pharmaceuticals, Inc.
$177
Telix Pharmaceuticals
$149
PFIZER INC.
$100
Top 3 companies account for 73.0% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$336,666
Exelixis Inc.
$249,681
Bayer HealthCare Pharmaceuticals Inc.
$215,428
PFIZER INC.
$90,907
GENZYME CORPORATION
$52,154
Bayer Healthcare Pharmaceuticals Inc.
$43,021
Astellas Pharma US Inc
$39,512
Alkermes, Inc.
$25,344
Merck Sharp & Dohme Corporation
$22,526
EMD Serono, Inc.
$16,128
Gilead Sciences, Inc.
$15,787
NOVARTIS PHARMACEUTICALS CORPORATION
$13,296
EISAI INC.
$13,276
Merck Sharp & Dohme LLC
$12,879
Advanced Accelerator Applications
$12,519
Genentech USA, Inc.
$10,369
Novartis Pharmaceuticals Corporation
$7,920
Aveo Pharmaceuticals, Inc.
$5,663
Genentech, Inc.
$5,064
Seagen Inc.
$4,506
EMD Serono Research & Development Institute, Inc.
$3,800
Pfizer Inc.
$3,400
Sumitomo Pharma America, Inc.
$3,100
Helsinn Healthcare SA
$3,000
PFIZER INTERNATIONAL LLC
$2,573
AVEO Pharmaceuticals, Inc.
$2,320
AstraZeneca Pharmaceuticals LP
$2,128
Eisai Inc.
$1,875
Aadi Bioscience, Inc.
$1,500
Telix Pharmaceuticals
$1,215
Janssen Scientific Affairs, LLC
$818
Celgene Corporation
$518
Olympus America Inc.
$134
COMSORT, Inc
$100
Augmenix, Inc.
$18
Janssen Pharmaceuticals, Inc
$12
Top 3 companies account for 65.8% of all-time payments
Associated products mentioned in payments ›
BAVENCIO · Bavencio · CABOMETYX · Cabometyx · ELIQUIS · ENZALUTAMIDE · Erleada · FOTIVDA · FYARRO · ILLUCCIX · IMFINZI · INLYTA · JEVTANA · KEYTRUDA · LUTATHERA · Lenvima · NO PRODUCT DISCUSSED · Nubeqa · OPDIVO · ORGOVYX · PADCEV · PLUVICTO · REBLOZYL · SUTENT · SpaceOAR · TECENTRIQ · Trodelvy · Truqap · VOTRIENT · XTANDI · Xofigo · Xtandi · iTIND System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (84%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for medical oncology in MI.

Looking for a medical oncology specialist in Ann Arbor?
Compare medical oncologists in the Ann Arbor area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
27
Per 100K population
7.3
County median income
$87,156
Nearest hospital
UNIVERSITY OF MICHIGAN HEALTH SYSTEM
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Vaishampayan is a clinical cardiology specialist, with moderate Medicare volume, with speaking/promotional industry engagement in the top 1% of MI peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Vaishampayan experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Vaishampayan performed 84 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vaishampayan receive payments from pharmaceutical companies?
Yes. Dr. Vaishampayan received a total of $1,219,156 from 36 companies across 1,018 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vaishampayan's costs compare to other medical oncologists in Ann Arbor?
Dr. Vaishampayan's average Medicare payment per service is $75. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vaishampayan) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Medical Oncologists in Ann Arbor
Browse medical oncologists in Ann Arbor ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in MI
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in MI
Which MI medical oncologists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →